Clinical Trials Logo

Clinical Trial Summary

This is a single-arm phase I/Ib study of crenolanib combined with ramucirumab/paclitaxel as second line therapy for patients with advanced/metastatic adenocarcinoma of the esophagus, GEJ or stomach. Patients will be enrolled in two phases; dose escalation phase and dose expansion phase.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03193918
Study type Interventional
Source Arog Pharmaceuticals, Inc.
Contact
Status Completed
Phase Phase 1
Start date April 14, 2017
Completion date July 15, 2020

See also
  Status Clinical Trial Phase
Completed NCT02234596 - Nintedanib in Patients With Advanced Esophagogastric Cancer Phase 2
Active, not recruiting NCT05268510 - Chemotherapy and Pembrolizumab, Followed by Pembrolizumab and Olaparib as Firstline Therapy in Her-2 Negative Gastric/GEJ Adenocarcinoma Phase 2
Recruiting NCT04219137 - Molecular Characteristics of Gastroesophageal Adenocarcinoma (MOCHA): A Prospective Feasibility Study
Completed NCT03921021 - Phase 2 Study of Telomelysin (OBP-301) in Combination With Pembrolizumab in Esophagogastric Adenocarcinoma Phase 2
Active, not recruiting NCT05504720 - Evaluating Pembrolizumab, Trastuzumab and FLOT as Perioperative Treatment of HER2-positive, Localized Esophagogastric Adenocarcinoma Phase 2
Withdrawn NCT02856867 - Nintedanib Plus mFOLFOX6 for Previously Untreated Metastatic Esophagogastric Adenocarcinoma (MEGAN) Phase 2
Recruiting NCT06123468 - Study Evaluating Treatment of Sacituzumab-govitecan for Patients With Metastatic Esophagogastric Adenocarcinoma Phase 1/Phase 2